IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation

Molecular and Cellular Biology

Volumn 32, Issue 23, 2012, Pages 4756-4768

  Shen, Rhine R ^a,c   Zhou, Alicia Y ^a,c   Kim, Eejung ^a,c   Lim, Elgene ^a   Habelhah, Hasem ^d   Hahn, William C ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UBIQUITINATION;

AMINO ACID SEQUENCE; ANIMALS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYSTEINE ENDOPEPTIDASES; DOWN-REGULATION; EPITHELIAL CELLS; FEMALE; HEK293 CELLS; HUMANS; I-KAPPA B KINASE; MICE; NF-KAPPA B; NIH 3T3 CELLS; NUCLEAR PORE COMPLEX PROTEINS; PHOSPHORYLATION; RNA-BINDING PROTEINS; TNF RECEPTOR-ASSOCIATED FACTOR 2; UBIQUITINATION;

EID: 84871902988     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00468-12     Document Type: Article

References (35)

1. Abbott DW, Wilkins A, Asara JM, Cantley LC. 2004. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr. Biol. 14:2217-2227.
2. Au PY, Yeh WC. 2007. Physiological roles and mechanisms of signaling by TRAF2 and TRAF5. Adv. Exp. Med. Biol. 597:32- 47.
3. Blackwell K, et al. 2009. TRAF2 phosphorylation modulates tumor necrosis factor alpha-induced gene expression and cell resistance to apoptosis. Mol. Cell. Biol. 29:303-314.
4. Boehm JS, et al. 2007. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129:1065-1079.
5. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. 2003. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424:797- 801.
6. Chau TL, et al. 2008. Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated? Trends Biochem. Sci. 33:171-180.
7. Chen ZJ. 2005. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 7:758 -765.
8. Compagno M, et al. 2009. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459:717-721.
9. Fitzgerald KA, et al. 2003. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4:491- 496.
10. Ghosh S, Hayden MS. 2008. New regulators of NF-kappaB in inflammation. Nat. Rev. Immunol. 8:837- 848.
11. Greten FR, et al. 2004. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285-296.
12. Gyrd-Hansen M, Meier P. 2010. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 10: 561-574.
13. Habelhah H, et al. 2004. Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. EMBO J. 23:322-332.
14. Hutti JE, et al. 2004. A rapid method for determining protein kinase phosphorylation specificity. Nat. Methods 1:27-29.
15. Hutti JE, et al. 2009. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol. Cell 34:461- 472.
16. Karin M. 2006. Nuclear factor-kappaB in cancer development and progression. Nature 441:431- 436.
17. Karin M, Greten FR. 2005. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5:749 -759.
18. Kovalenko A, et al. 2003. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424:801- 805.
19. Krappmann D, Scheidereit C. 2005. A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways. EMBO Rep. 6:321-326.
20. Lenz G, et al. 2008. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319:1676 -1679.
21. Li S, Wang L, Dorf ME. 2009. PKC phosphorylation of TRAF2 mediates IKKalpha/beta recruitment and K63-linked polyubiquitination. Mol. Cell 33:30-42.
22. Meylan E, et al. 2009. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462:104 -107.
23. Novak U, et al. 2009. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 113:4918-4921.
24. Perkins ND. 2007. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 8:49-62.
25. Pikarsky E, et al. 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461- 466.
26. Pomerantz JL, Baltimore D. 1999. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J. 18:6694-6704.
27. Reiley W, Zhang M, Wu X, Granger E, Sun SC. 2005. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol. Cell. Biol. 25:3886 -3895.
28. Rothe M, Sarma V, Dixit VM, Goeddel DV. 1995. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science 269:1424- 1427.
29. Shi CS, Kehrl JH. 2003. Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor- associated factor 2 (TRAF2). J. Biol. Chem. 278:15429 -15434.
30. Sun SC. 2008. Deubiquitylation and regulation of the immune response. Nat. Rev. Immunol. 8:501-511.
31. Thomas GS, Zhang L, Blackwell K, Habelhah H. 2009. Phosphorylation of TRAF2 within its RING domain inhibits stress-induced cell death by promoting IKK and suppressing JNK activation. Cancer Res. 69:3665- 3672.
32. Trompouki E, et al. 2003. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424:793-796.
33. Vince JE, et al. 2009. TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (TNF) to efficiently activate NF-{kappa}B and to prevent TNF-induced apoptosis. J. Biol. Chem. 284:35906 -35915.
34. Wu CJ, et al. 2005. TNF-alpha induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. EMBO J. 24:1886 -1898.
35. Zhang L, Blackwell K, Altaeva A, Shi Z, Habelhah H. 2011. TRAF2 phosphorylation promotes NF-{kappa}B-dependent gene expression and inhibits oxidative stress-induced cell death. Mol. Biol. Cell 22: 128 -140.